Skip to main content

Table 3 Risk factors for unfavourable treatment outcomes among the MDR-TB patients received non-MDR-TB treatment

From: Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study

Factors Patients with non-MDR-TB treatment Odds ratio (95% CI) Adjusted odds ratio (95% CI) a
Favourable outcomes (n = 13) Unfavourable outcomes (n = 24)
Age (mean±SD) 43.2 ± 19.8 55.1 ± 14.1 0.96 (0.91–1.00)  
Male 12 (92.3) 22 (91.7) 1.09 (0.09–13.3)  
Study sites in
 Western 10 (76.9) 20 (83.3) 1  
 Eastern 3 (23.1) 4 (16.7) 1.50 (0.28–8.04)  
Body mass index (mean±SD) 21.4 ± 2.2 20.1 ± 2.2 1.33 (0.95–1.86) 1.41 (0.97–2.06)
Education
 Primary school or below 4 (30.8) 20 (83.3) 1 1
 Junior high school or above 9 (69.2) 4 (16.7) 11.3 (2.29–55.4) 9.78 (1.77–54.0)
Married 8 (61.5) 11 (45.8) 1.89 (0.48–7.49) 1.69 (0.32–8.93)
Health insurance 13 (100.0) 23 (95.8)   
Haemoptysis 3 (23.1) 8 (33.3) 0.60 (0.13–2.81) 0.53 (0.10–2.84)
Tuberculosis treatment history 4 (30.8) 14 (58.3) 0.32 (0.08–1.33) 0.15 (0.02–1.05)
Pulmonary cavities 7 (53.8) 9 (37.5) 1.94 (0.49–7.64) 1.86 (0.37–9.19)
DST pattern
 MDR 7 (53.8) 9 (37.5) 1 1
 Pre-XDR and XDR 6 (46.2) 15 (62.5) 0.51 (0.13–2.02) 0.64 (0.14–2.84)
Strain family (n = 33)
 Non-Beijing family 2 (16.7) 2 (9.5) 1 1
 Beijing family 10 (83.3) 19 (90.5) 0.53 (0.06–4.32) 0.90 (0.08–10.2)
Total delay (days)
  ≤ 90.0 9 (69.2) 12 (50.0) 1 1
  > 90.0 4 (30.8) 12 (50.0) 0.44 (0.11–1.85) 0.36 (0.05–2.39)
  1. DNA was failure to extract from six Mycobacterium tuberculosis isolates. Two patients were once reported as treatment success but were lost at the last yearly follow-up, thus excluded from the analysis. MDR Multidrug-resistant, SD Standard deviation, DST Drug susceptibility testing, XDR Extensively drug-resistant
  2. aAdjusted by age, gender and study sites